As a human anti-IL-1β monoclonal antibody, Canakinumab (45-week treatment) showed no statistical analysis provided for lung function changes.159 The receptor inhibitor tocilizumab is an available IL-6 inhibitor with confirmed efficacy in rheumatoid arthritis, but clinical trials in COPD require further study. This evidence concerns the gene IL6 and chronic obstructive pulmonary disease.